Arazine™ and second generation compounds constitute a new class of non-steroidal anti-inflammatories that have broad utility over multiple therapeutic areas, including:
In vitro studies have shown that Arazine™ and its derivatives are capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. Furthermore, our results demonstrate Arazine™ successfully blocks neutrophil infiltration in vivo.
GPM Compounds have an Excellent Safety Profile
Arazine™, our lead GPM compound is in essence a naturally occurring amino acid that is readily metabolized once it enters the body. This along with several other factors contributes to its excellent safety profile. Studies show Arazine™:
Is hypoallergenic
Does not cause corneal corrosion when applied to the eye
Does not cause irritation or skin thinning
Acts only at the site of topical application
Is not carcinogenic (Ames Test)
Causes no skin sensitization or irritation in humans. Arazine™ has caused no adverse reactions in numerous acute and chronic human-use studies.
Arazine™: Mechanism of Action
Many important signaling proteins contain a C-terminal CAAX motif that undergoes prenylation, proteolysis and methylation for proper localization in the cell. Arazine™ a small molecule mimic of this C-terminal processing, can enter cells and compete with prenylated G-proteins for sites of interaction with receptors in the membrane and/or compete with prenylated G-proteins as a substrate for ICMT. Together, these effects inhibit downstream signaling for inflammation.
Interested in a job at Signum? Visit our job postings section for a listing of our open positions.